ReviewInternational journal of particle therapy2026
Advancing Particle Therapy to Improve Cancer Care: Report on "2nd World Forum on Particle Therapy".
Review in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Purpose: Charged particle therapy (PT), including proton beam therapy (PBT) and carbon ion radiation therapy (CIRT), offers potential advantages for selected patients. A key challenge remains in how to expand access to PT to maximize clinical benefit. Methods: Eighty-one international PT leaders convened at the 2nd World Forum to discuss strategies for advancing PT globally. Results: Recent PBT trials have shown reduced toxicity in oropharyngeal and advanced esophageal cancer, improved local control in hepatocellular carcinoma, and improved survival in patients with leptomeningeal and oropharygeal cancer. In contrast, there was no difference in toxicity nor progression-free survival in low-to-intermediate risk prostate cancer, and no cognitive benefit seen in adult glioblastoma. Additional trials results are awaited. Vendor financial support has been instrumental in enabling many studies.CIRT trials remain limited, though several are ongoing. Further development and harmonization of relative biological effectiveness (RBE) models is crucial. Helium therapy and oxygen therapy require exploration. Heavy ions may enhance immune response through more complex DNA damage than X-rays. This potential synergy with immunotherapy should be explored further.Second-generation trials should leverage the biological advantages of PT, target promising sites and diseases, include molecular diagnostics, and explore hypofractionation.Indications for PBT are expanding, supported by emerging evidence. More studies are needed, including developments in clinical endpoints and integration of biological data on tumors and normal tissues. Follow up of all PT patients is needed, with pooling of international data. Trials are needed to define the role of heavier ions and their immune effects. Conclusions: Large, definitive, "Champion Studies," demonstrating survival benefit over established therapy are essential. International collaboration with strong administrative and financial support will be key. A meeting to develop such a study is strongly recommended. The faster and more efficiently the community can work, the more patients will benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.